Immutep targets $100m for lung cancer drug trial tests
Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
TOX | News: TOX ASX Says Tox Free Solutions To Be Removed From Official List Of ASX On May 28 At Close | 30/05/18 | 1 | 1.8K | |||
|
|||||||
TOX | Ann: Removal from Official List | 28/05/18 | 0 | 1.3K | |||
|
|||||||
TOX | Ann: Appendix 3Z - R Allen | 25/05/18 | 0 | 487 | |||
|
|||||||
TOX | Ann: Appendix 3Z - M Humphris | 25/05/18 | 0 | 457 | |||
|
|||||||
TOX | Ann: Appendix 3Z - K Hirschfeld | 25/05/18 | 0 | 426 | |||
|
|||||||
TOX | Ann: Appendix 3Z - B McKinnon | 25/05/18 | 0 | 442 | |||
|
|||||||
TOX | Ann: Appendix 3Z - S Gostlow | 25/05/18 | 0 | 456 | |||
|
See All Discussions